Rauwolf KK, Floeth M, Kerl Okay, Schaumburg F, Groll AH. Toxoplasmosis after allogeneic haematopoietic cell transplantation—illness burden and approaches to prognosis, prevention and administration in adults and youngsters. Clin Microbiol Infect. 2021;27:378–88.
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz Okay, Storek J, et al. Tips for Stopping Infectious Issues amongst Hematopoietic Cell Transplantation Recipients: A International Perspective. Biol Blood Marrow Transplant. 2009;15:1143–238.
on behalf of the Infectious Illnesses Working Occasion of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation), Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, et al. Infectious ailments in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis technique pointers 2016. Ann Hematol. 2016;95:1435–55.
Martino R, Bretagne S, Einsele H, Maertens J, Ullmann AJ, Parody R, et al. Early Detection of Toxoplasma An infection by Molecular Monitoring of Toxoplasma gondii in Peripheral Blood Samples after Allogeneic Stem Cell Transplantation. Clin Infect Dis. 2005;40:67–78.
Lim Z, Baker B, Zuckermann M, Wade JJ, Ceesay M, Ho AYL, et al. Toxoplasmosis following alemtuzumab primarily based allogeneic haematopoietic stem cell transplantation. J Infect. 2007;54:e83–6.
Bretagne S, Costa JM, Foulet F, Jabot-Lestang L, Baud-Camus F, Cordonnier C. Potential examine of toxoplasma reactivation by polymerase chain response in allogeneic stem-cell transplant recipients: T. gondii PCR for SCT recipients. Transpl Infect Dis. 2000;2:127–32.
Robin C, Leclerc M, Angebault C, Redjoul R, Beckerich F, Cabanne L, et al. Toxoplasmosis as an Early Complication of Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019;25:2510–3.
De Medeiros BC, De Medeiros CR, Werner B, Loddo G, Pasquini R, Bleggi-Torres LF. Disseminated toxoplasmosis after bone marrow transplantation: report of 9 circumstances: Disseminated toxoplasmosis after BMT. Transpl Infect Dis. 2001;3:24–8.
Mele A, Paterson P, Prentice H, Leoni P, Kibbler C. Toxoplasmosis in bone marrow transplantation: a report of two circumstances and systematic evaluation of the literature. Bone Marrow Transplant. 2002;29:691–8.
Derouin F, Devergie A, Auber P, Gluckman E, Beauvais B, Garin YJF, et al. Toxoplasmosis in Bone Marrow-Transplant Recipients: Report of Seven Circumstances and Evaluate. Clin Infect Dis. 1992;15:267–70.
Matsuo Y, Takeishi S, Miyamoto T, Nonami A, Kikushige Y, Kunisaki Y, et al. Toxoplasmosis encephalitis following extreme graft-vs.-host illness after allogeneic hematopoietic stem cell transplantation: 17 yr expertise in Fukuoka BMT group: Toxoplasmosis encephalitis after allo-HSCT. Eur J Haematol. 2007;79:317–21.
Redjoul R, Robin C, Foulet F, Leclerc M, Beckerich F, Cabanne L, et al. Pneumocystis jirovecii pneumonia prophylaxis in allogeneic hematopoietic cell transplant recipients: can we all the time comply with the rules? Bone Marrow Transplant. 2019;54:1082–8.
Martino R, Maertens J, Bretagne S, Rovira M, Deconinck E, Ullmann AJ, et al. Toxoplasmosis after Hematopoietic Stem Cell Transplantation. Clin Infect Dis. 2000;31:1188–94.
Menotti J, Garin YJF, Thulliez P, Sérugue MC, Stanislawiak J, Ribaud P, et al. Analysis of a brand new 5’-nuclease real-time PCR assay concentrating on the Toxoplasma gondii AF146527 genomic repeat. Clin Microbiol Infect. 2010;16:363–8.
Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT handbook: hematopoietic stem cell transplantation and mobile therapies [Internet]. Cham: Springer Worldwide Publishing; 2019. http://hyperlink.springer.com/10.1007/978-3-030-02278-5
Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE Tips: Minimal Info for Publication of Quantitative Actual-Time PCR Experiments. Clin Chem. 2009;55:611–22.
Foot AB, Garin YJ, Ribaud P, Devergie A, Derouin F, Gluckman E. Prophylaxis of toxoplasmosis an infection with pyrimethamine/sulfadoxine (Fansidar) in bone marrow transplant recipients. Bone Marrow Transplant. 1994;14:241–5.
Aerts R, Mercier T, Beckers M, Schoemans H, Lagrou Okay, Maertens J. Toxoplasmosis after allogeneic haematopoietic cell transplantation: expertise utilizing a PCR-guided pre-emptive strategy. Clin Microbiol Infect. 2022;28:440–5.
Conrad A, Le Maréchal M, Dupont D, Ducastelle-Leprêtre S, Balsat M, Labussière-Pockets H, et al. A matched case–management examine of toxoplasmosis after allogeneic haematopoietic stem cell transplantation: nonetheless a devastating complication. Clin Microbiol Infect. 2016;22:636–41.
Fricker‐Hidalgo H, Bulabois C, Brenier‐Pinchart M, Hamidfar R, Garban F, Brion J, et al. Analysis of Toxoplasmosis after Allogeneic Stem Cell Transplantation: Outcomes of DNA Detection and Serological Methods. Clin Infect Dis. 2009;48:e9–15.
Paccoud O, Guitard J, Labopin M, Surgers L, Malard F, Battipaglia G, et al. Options of Toxoplasma gondii reactivation after allogeneic hematopoietic stem-cell transplantation in a excessive seroprevalence setting. Bone Marrow Transpl. 2020;55:93–9.
Meers S, Lagrou Okay, Theunissen Okay, Dierickx D, Delforge M, Devos T, et al. Myeloablative Conditioning Predisposes Sufferers for Toxoplasma gondii Reactivation after Allogeneic Stem Cell Transplantation. Clin Infect Dis. 2010;50:1127–34.
Guigue N, Léon L, Hamane S, Gits-Muselli M, Le Strat Y, Alanio A, et al. Corrigendum: Steady Decline of Toxoplasma gondii Seroprevalence in Hospital: A 1997–2014 Longitudinal Examine in Paris, France. Entrance Microbiol. 2018;9:2814.
Foroutan-Rad M, Majidiani H, Dalvand S, Daryani A, Kooti W, Saki J, et al. Toxoplasmosis in Blood Donors: A Systematic Evaluate and Meta-Evaluation. Transfus Med Rev. 2016;30:116–22.
Reischl U, Bretagne S, Krüger D, Ernault P, Costa JM. Comparability of two DNA targets for the prognosis of Toxoplasmosis by real-time PCR utilizing fluorescence resonance power switch hybridization probes. BMC Infect Dis. 2003;3:7.
Isa F, Saito Okay, Huang YT, Schuetz A, Babady NE, Salvatore S, et al. Implementation of Molecular Surveillance After a Cluster of Deadly Toxoplasmosis at 2 Neighboring Transplant Facilities. Clin Infect Dis. 2016;63:565–8.
Bretagne S, Costa JM, Kuentz M, Simon D, Vidaud M, Fortel I, et al. Late toxoplasmosis evidenced by PCR in a marrow transplant recipient. Bone Marrow Transplant. 1995;15:809–11.
Chandrasekar P, Momin F. The Bone Marrow Transplant Crew. Disseminated toxoplasmosis in marrow recipients: a report of three circumstances and a evaluation of the literature. Bone Marrow Transplant. 1997;19:685–9.
Gajurel Okay, Dhakal R, Montoya JG. Toxoplasma prophylaxis in haematopoietic cell transplant recipients: a evaluation of the literature and suggestions. Curr Opin Infect Dis. 2015;28:283–92.
Štajner T, Vujić D, Srbljanović J, Bauman N, Zečević Ž, Simić M, et al. Threat of reactivated toxoplasmosis in haematopoietic stem cell transplant recipients: a potential cohort examine in a setting withholding prophylaxis. Clin Microbiol Infect. 2022;28:733.e1–733.e5.
Dupont D, Fricker-Hidalgo H, Brenier-Pinchart MP, Garnaud C, Wallon M, Pelloux H. Serology for Toxoplasma in Immunocompromised Sufferers: Nonetheless Helpful? Developments Parasitol. 2021;37:205–13.
